Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462447 · ClinicalTrials.gov registry record
Carbon-11 Labeled Sarcosine in Prostate Cancer
A clinical trial, sponsored by University of Michigan.
- Completed
- Registry status
- 20
- Enrollment target
NCT02462447: Completed study, sponsored by University of Michigan.
NCT02462447 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02462447 has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Men with and without prostate cancer will have a PET/CT scan that measures the level of the amino acid sarcosine. PET is a scanning method that uses short lived radioactivity.
Interventions
- DRUG 11C-sarcosine
- DRUG 11C-choline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-02-08 |
What the finished NCT02462447 record still lists
NCT02462447 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which 11C-sarcosine is the first listed.
NCT02462447 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02462447 about?
NCT02462447 is a clinical study titled "Carbon-11 Labeled Sarcosine in Prostate Cancer". Men with and without prostate cancer will have a PET/CT scan that measures the level of the amino acid sarcosine. PET is a scanning method that uses short lived radioactivity.
What is the current status of trial NCT02462447?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2015-06. Estimated completion is 2017-02-08.
What interventions are being tested in trial NCT02462447?
The interventions under investigation include: 11C-sarcosine (DRUG), 11C-choline (DRUG).
Who is sponsoring clinical trial NCT02462447?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia